D-glucopyranose, oligomers, xylityl glycosides and 1,4 anhydro D-xylitol and D-xylitol

Endpoint summary

Description of key information

2 acute oral and dermal toxicity studies were performed. No mortality was observed.
LD50 oral and dermal routes > 2000 mg/kg bw/d

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: OCDE guideline, GLP study

Qualifier:

according to guideline

Guideline:

OECD Guideline 401 (Acute Oral Toxicity)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.1 (Acute Toxicity (Oral))

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

OFA Sprague-Dawley rats (SPF caw) originated from IFFA CREDO (69210 L'Arbresle-France), were kept during a 5-day acclimatisation period. At the beginning of the study, the animals weight was contained between 176 g and 210g (males) and between 159g and 182g (females).

Route of administration:

oral: gavage

Vehicle:

water

Remarks:

aucun

Details on oral exposure:

The administration was done by force-feeding under a volume of 1.51 mL/kg body weight using a suitable syringe graduated fitted with an oesophagal metal canula. The dose received was 2000 mg/kg bw.

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5

Control animals:

yes

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Mortality:

Male: >= 2000 mg/kg bw; Number of animals: 5; Number of deaths: 0
Female: >= 2000 mg/kg bw; Number of animals: 5; Number of deaths: 0

Clinical signs:

other: Signs of toxicity related to dose levels: no clinical signs related to the administration of the test product. Evolution du poids normal sur 14 j.

Gross pathology:

Effects on organs:
macrsocopical examintaion of the animals at the end of the study did not reveal treatment related changes.

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The LD 50 of the product LCA 01006 is higher than 2000 mg/kg body weight by oral route in the rat.
According to the criteria for classification, packaging and labelling of dangerous substances in accordance with EEC directives 67/548 and 93/21, the product LCA 01006 must not be classified "R28: very toxic if swallowed", "R25: toxic if swallowed" or " R22: harmful if swallowed".

Executive summary:

The product LCA 01006 was administrated to a group of 10 Sprague-Dawley rats (5 males and 5 females) at the single dose of 2000 mg/kg body weight according to the experimental protocol established on the basis of the official method as defined in the OECD guideline n°401 dated February 24th, 1987 and the test method B.1 of the Directive n°92/69/EEC dated December 29th, 1992.

No mortality occured during the study.

No clinical signs related ti the administration of the test ptoduct were observed. The body weight evolution of the animals remained normal throughout the study, similar between treated and control animals.

The macrsocopical examintaion of the animals at the end of the study did not reveal treatment related changes.

In conclusion, the LD50 of the product LCA 01006 is higher than 2000 mg/kg body weight by oral route in the rat.

According to the criteria for classification, packaging and labelling of dangerous substances in accordance with EEC directives 67/548 and 93/21, the product LCA 01006 must not be classified.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Quality of whole database:

The acute oral toxicity study was performed according to the OECD guideline n°401
LD50> 2000 mg/kg bw/d

Acute toxicity: via inhalation route

Link to relevant study records

Reference

Endpoint:

acute toxicity: inhalation

Data waiving:

study scientifically not necessary / other information available

Justification for data waiving:

the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: GLP study, OCDE guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Remarks:

2003-02-13

Test type:

standard acute method

Limit test:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

Five male and five female Sprague-Dawley CD (Crl: CD® (SD) IGS BR) strain rats were supplied
by Charles River (UK) Ltd, Margate, Kent, UK. On receipt the animals were randomly allocated
to cages. The females were nulliparous and non-pregnant. After an acclimatisation period of at
least five days the animals were selected at random and given a number unique within the study
by indelible ink-marking on the tail and a number written on a cage card. At the start of the study
the animals weighed at least 200 g, and were eight to twelve weeks of age. The weight variation
did not exceed ± 20% of the mean weight for each sex.
The animals were housed in suspended solid-floor polypropylene cages furnished with
woodflakes. The animals were housed individually during the 24-hour exposure period and in
groups of five, by sex, for the remainder of the study. Free access to mains drinking water and
food (Certified Rat and Mouse Diet (Code 5LF2) supplied by BCM IPS Limited, London, UK)
was allowed throughout the study. The diet, drinking water and bedding were routinely analysed
and were considered not to contain any contaminants that could reasonably be expected to affect
the purpose or integrity of the study.
The temperature and relative humidity were set to achieve limits of 19 to 25°C and 30 to 70%
respectively. Any occasional deviations from these targets were considered not to have affected
the purpose or integrity of the study. The rate of air exchange was at least fifteen changes per
hour and the lighting was controlled by a time switch to give twelve hours continuous light (06:00
to 18:00) and twelve hours darkness.
The animals were provided with environmental enrichment items which were considered not to
contain any contaminant of a level that might have affected the purpose or integrity of the study.

Type of coverage:

semiocclusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

The appropriate amount of test material was applied as evenly as possible to an area of shorn skin
(approximately 10% of the total body surface area). A piece of surgical gauze was placed over
the treatment area and semi-occluded with a piece of self-adhesive bandage. The animals were
caged individually for the 24-hour exposure period. Shortly after dosing the dressings were
examined to ensure that they were securely in place.
After the 24-hour contact period the bandage was carefully removed and the treated skin and
surrounding hair wiped with cotton wool moistened with distilled water to remove any residual
test material. The animals were returned to group housing for the remainder of the study period.

Duration of exposure:

24 h

Doses:

2000 mg/kg pc

Details on study design:

The animals were observed for deaths or overt signs of toxicity ½, 1, 2 and 4 hours after dosing
and subsequently once daily for fourteen days.
After removal of the dressings and subsequently once daily for fourteen days, the test sites were
examined for evidence of primary irritation and scored according to the following scale from
Draize J H (1977) "Dermal and Eye Toxicity Tests" In: Principles and Procedures for Evaluating
the Toxicity of Household Substances, National Academy of Sciences, Washington DC p.31

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Sex:

male/female

Dose descriptor:

LD0

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

Male: 2000 mg/kg bw; Number of animals: 5; Number of deaths: 0
Female: 2000 mg/kg bw; Number of animals: 5; Number of deaths: 0

Clinical signs:

other: There were no signs of systemic toxicity.

Gross pathology:

No abnormalities were noted at necropsy.

Other findings:

There were no signs of dermal irritation.

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The acute dermal median lethal dose (LD50) and the maximum sub-lethal dose (LD0) of the test
material in the Sprague-Dawley CD strain rat were found to be greater than 2000 mg/kg
bodyweight.

Executive summary:

Introduction.

The study was performed to assess the acute dermal toxicity of the test material in the Sprague-Dawley CD strain rat. The method was designed to meet the requirements of the following: 􀂃 OECD Guidelines for the Testing of Chemicals No. 402 “Acute Dermal Toxicity” (adopted 24 February 1987) 􀂃 Method B3 Acute Toxicity (Dermal) of Commission Directive 92/69/EEC

Method.

A group of ten animals (five males and five females) was given a single, 24-hour, semi-occluded dermal application of the test material to intact skin at a dose level of 2000 mg/kg bodyweight.

Clinical signs and bodyweight development were monitored during the study. All animals were subjected to gross necropsy.

Mortality. There were no deaths. Clinical Observations. There were no signs of systemic toxicity.

Dermal Irritation. There were no signs of dermal irritation.

Bodyweight. All animals showed expected gains in bodyweight over the study period. Necropsy. No abnormalities were noted at necropsy.

Conclusion. The acute dermal median lethal dose (LD50) and the maximum sub-lethal dose (LD0) of the test material in the Sprague-Dawley CD strain rat were found to be greater than 2000 mg/kg bodyweight.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

LD50

Value:

2 000 mg/kg bw

Additional information

Justification for selection of acute toxicity – inhalation endpoint
Based on exposure considerations, this endpoint is not relevant for the registered substance.
This substance is not volatile (vapor pressure of 3.6 10-4 Pa at 25°C).
No exposition is expected via this route.

Justification for selection of acute toxicity – dermal endpoint
The acute oral toxicity study was performed according to the OECD guideline n°402
LD50> 2000 mg/kg bw/d

Justification for classification or non-classification

The test item is not classified for acute toxicity according to the CLP regulation 1272/2008/EC.